Aker ASA A Shs (AKAAF) 19.6300 $AKAAF
Inspirion Delivery Technologies Announces FDA Acceptance of MorphaBond(TM) ER (morphine sulfate extended-release) New Drug Application; Its Investigational Abuse-Deterrent, Extended-Release Opioid
PR Newswire - Mon Feb 09, 7:25PM CST
Inspirion Delivery Technologies, LLC ("IDT"

, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group ("TPG"

, announced that the U.S. Food & Drug Administration ("FDA"

has accepted for filing the New Drug Application ("NDA"

submitted on November 21, 2014 for its investigational drug, MorphaBond(TM) ER, an extended-release (ER), abuse-deterrent formulation of morphine. MorphaBond ER is an opioid analgesic, utilizing IDT's patent-protected, proprietary technology. This NDA requests FDA approval of MorphaBond ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. TPG, the Norwegian based 50/50 joint venture between Aker ASA and Lindsay Goldberg LLC, is IDTs investment partner in a number of opioid development programs, including MorphaBond ER.
Aker AS: My Best Idea To Play Oil (Which Isn't Really In Oil)
Bram de Haas - at Seeking Alpha - Tue Dec 30, 2:57PM CST